跳至主要内容
临床试验/NCT00334334
NCT00334334已完成3 期

To Assess Safety, Reactogenicity and Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Co-administered With DTPa-combined Vaccines and MenC or Hib-MenC Vaccines During the First 6 Months of Age.

GlaxoSmithKline67 个研究点 分布在 3 个国家目标入组 1,572 人开始时间: 2006年6月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
1,572
试验地点
67
主要终点
Post at least 1 dose: rectal fever >39°C

研究概览

简要总结

Three dose primary vaccination of healthy infants between 6 to 16 weeks of age at the time of the first vaccination against Streptococcus pneumonia, Neisseria meningitidis and Haemophilus influenzae type b.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
6 Weeks 至 16 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • male or female between, and including, 6-16 weeks (42 to 118 days) of age at the time of the first vaccination, free of obvious health problems and with written informed consent obtained from the parent/guardian of the subject.

排除标准

  • use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the entire study period.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting one month before each dose of vaccine(s) and ending 7 days after dose 1 and dose 2 or 1 month after dose
  • Previous vaccinations against diseases which are targeted by the vaccines used in the study.

结局指标

主要结局

Post at least 1 dose: rectal fever >39°C

次要结局

  • Post each dose: solicited/unsolicited AEs (4/31 days), SAEs (whole study); post dose 2 & 3: Ab conc to vaccine antigens

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (67)

Loading locations...

相似试验